As per our recent analysis, Preventive Vaccine Market in Middle East & Africa is deemed to have decent growth opportunities during the forecast period.
Due to increased healthcare expenditure, new vaccine development, and rising demand for preventive vaccines, the Middle East and Africa preventive vaccines market is expected to grow at a healthy growth rate during the forecast period. Preventive immunizations have grown in some disease areas, such as polio, but it has yet to establish itself in others. Despite these disparities, the market continues to grow, owing to variable degrees of rising demand for vaccination for different diseases throughout time. The increasing prevalence of infectious illnesses, innovative technology in vaccine research, higher financing from government and international organizations, and improved awareness of preventative care contribute to the growth of the Middle East and Africa preventive vaccines market.
Infectious diseases are among the world's leading killers, posing some of the world's most severe health and security risks to the Middle East and Africa. Contagious infections are among the most common causes of death. Scientists from all over the world are currently conducting research, sharing information, building laboratory capacity in developing countries, and establishing surveillance networks in the Middle East and Africa to prevent and control the spread of these diseases through preventive vaccinations.
Healthcare expenditures are skyrocketing, and prevention is becoming increasingly popular. Vaccination costs have risen from single digits to triple digits several times in the last two decades, posing severe challenges for doctors and their patients, as well as putting pressure on public health funds. The preventive vaccinations market in the Middle East and Africa is expected to grow due to rising healthcare costs, new vaccine research, and increased demand for preventive vaccines, particularly the new COVID-19 vaccines.
This research report has been segmented and sub-segmented the MEA preventive vaccines market into the following categories:
By Vaccine Type:
By End-User:
By Country:
The Middle East and Africa have a tiny part of global markets, with the UAE and Kuwait contributing the primary factor. The Advisory Committee for Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) regularly provides immunization recommendations for adults and children in the UAE. In addition, the United Arab Emirates boasts one of the vital healthcare systems in the Middle East and Africa, with immunization coverage that meets WHO recommendations. As a result, the region's preventive vaccination market is predicted to develop moderately throughout the forecast period.
The high frequency of infectious illnesses and increased spending by government and non-government organizations in vaccine development account for the Middle East and Africa's portion of the vaccines market. The expansion of the vaccines market in the Middle East and Africa is being driven by rising healthcare spending and disposable income, government initiatives, and the presence of a large patient population.
The industrial foundation, productivity, strengths, manufacturers, and current trends in the Middle East and Africa preventive vaccination market can assist enterprises in expanding their businesses and boosting financial success.
Furthermore, the market comprises recent collaborations, mergers, acquisitions, partnerships, and legislative frameworks in countries such as the United Arab Emirates and Kuwait, all of which impact the industry's trajectory. In addition, the market in the Middle East and Africa is being influenced by recent technological advancements and breakthroughs.
KEY MARKET PLAYERS:
Companies that dominate the MEA preventive vaccines market profiled in this report are GlaxoSmithKline, PLC, Bavarian Nordic, Merck and Company, CSL Limited, Novartis AG, Emergent BioSolutions Inc., Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Vaccine Type
5.1.1 Live, Attenuated Vaccines
5.1.2 Inactivted Vaccines
5.1.3 Toxoid Vaccines
5.1.4 Subunit vaccines
5.1.5 Conjugate vaccines
5.1.6 DNA vaccines
5.1.7 Recombinant vector vaccines
5.2 By End User
5.2.1 Paediatric Vaccine
5.2.1.1 Pneumococcal
5.2.1.2 MMR
5.2.1.3 Varicella
5.2.1.4 Hepatitis
5.2.1.5 Poliovirus
5.2.1.6 HIB
5.2.1.7 Others
5.2.2 Adult Vaccines
5.2.2.1 Influenza
5.2.2.2 Cervical Cancer
5.2.2.3 Hepatitis
5.2.2.4 Zoster
5.2.2.5 Others
6. Geographical Analysis
6.1 Introduction
6.2 Middle-East
6.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GlaxoSmithKline, plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck and Company
8.3 Bavarian Nordic
8.4 CSL Limited
8.5 Emergent BioSolutions Inc.
8.6 Novartis AG
8.7 Johnson and Johnson
8.8 MedImmune, LLC
8.9 Pfizer, Inc.
8.10 Sanofi Pasteur
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
